JP2016507575A5 - - Google Patents

Download PDF

Info

Publication number: JP2016507575A5
Authority: JP; Japan
Prior art keywords: compound; compound according; formula; group; alzheimer
Prior art date: 2014-02-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP2015557226A

Other languages

English (en)

Japanese (ja)

Other versions

JP6471100B2 (ja

JP2016507575A (ja

Filing date

2014-02-12

Publication date

2017-02-23

2014-02-12 Application filed filed Critical

2014-02-12 Priority claimed from PCT/US2014/016100 external-priority patent/WO2014127042A1/en

2016-03-10 Publication of JP2016507575A publication Critical patent/JP2016507575A/ja

2017-02-23 Publication of JP2016507575A5 publication Critical patent/JP2016507575A5/ja

2019-02-13 Application granted granted Critical

2019-02-13 Publication of JP6471100B2 publication Critical patent/JP6471100B2/ja

Status Active legal-status Critical Current

2034-02-12 Anticipated expiration legal-status Critical

Links

150000001875 compounds Chemical class 0.000 claims 30
208000024827 Alzheimer disease Diseases 0.000 claims 6
125000000217 alkyl group Chemical group 0.000 claims 6
229910052736 halogen Inorganic materials 0.000 claims 6
150000003839 salts Chemical class 0.000 claims 6
125000003118 aryl group Chemical group 0.000 claims 5
150000002367 halogens Chemical class 0.000 claims 5
125000001072 heteroaryl group Chemical group 0.000 claims 5
125000000753 cycloalkyl group Chemical group 0.000 claims 4
101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 claims 3
208000010877 cognitive disease Diseases 0.000 claims 3
238000009472 formulation Methods 0.000 claims 3
239000000203 mixture Substances 0.000 claims 3
206010064930 age-related macular degeneration Diseases 0.000 claims 2
125000003342 alkenyl group Chemical group 0.000 claims 2
125000003545 alkoxy group Chemical group 0.000 claims 2
125000000304 alkynyl group Chemical group 0.000 claims 2
125000001188 haloalkyl group Chemical group 0.000 claims 2
208000002780 macular degeneration Diseases 0.000 claims 2
125000003107 substituted aryl group Chemical group 0.000 claims 2
208000024891 symptom Diseases 0.000 claims 2
125000003866 trichloromethyl group Chemical group ClC(Cl)(Cl)* 0.000 claims 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
102100021257 Beta-secretase 1 Human genes 0.000 claims 1
208000031124 Dementia Alzheimer type Diseases 0.000 claims 1
241000124008 Mammalia Species 0.000 claims 1
239000000443 aerosol Substances 0.000 claims 1
239000003937 drug carrier Substances 0.000 claims 1
238000001990 intravenous administration Methods 0.000 claims 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
-1 monosubstituted phenyl Chemical group 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
125000004001 thioalkyl group Chemical group 0.000 claims 1
230000037317 transdermal delivery Effects 0.000 claims 1
0 CC(C*=CC)*N=CC Chemical compound CC(C*=CC)*N=CC 0.000 description 1

JP2015557226A 2013-02-12 2014-02-12 Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン Active JP6471100B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201361763830P	2013-02-12	2013-02-12
US61/763,830		2013-02-12
PCT/US2014/016100 WO2014127042A1 (en)	2013-02-12	2014-02-12	Hydantoins that modulate bace-mediated app processing

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2019005905A Division JP6773820B2 (ja)	2013-02-12	2019-01-17	Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン

Publications (3)

Publication Number	Publication Date
JP2016507575A JP2016507575A (ja)	2016-03-10
JP2016507575A5 true JP2016507575A5 (2)	2017-02-23
JP6471100B2 JP6471100B2 (ja)	2019-02-13

Family

ID=51354522

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP2015557226A Active JP6471100B2 (ja)	2013-02-12	2014-02-12	Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン
JP2019005905A Active JP6773820B2 (ja)	2013-02-12	2019-01-17	Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2019005905A Active JP6773820B2 (ja)	2013-02-12	2019-01-17	Ｂａｃｅ仲介性ａｐｐプロセシングを調節するヒダントイン

Country Status (11)

Country	Link
US (6)	US20140371283A1 (2)
EP (2)	EP3653609B1 (2)
JP (2)	JP6471100B2 (2)
KR (2)	KR102051485B1 (2)
CN (1)	CN104995176B (2)
AU (1)	AU2014216390B2 (2)
CA (1)	CA2899938C (2)
DK (1)	DK2956443T3 (2)
ES (2)	ES2975235T3 (2)
IL (1)	IL240555B (2)
WO (1)	WO2014127042A1 (2)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20140371283A1 (en)	2013-02-12	2014-12-18	Buck Institute For Research On Aging	Hydantoins that modulate bace-mediated app processing
KR102220260B1 (ko)	2015-02-18	2021-02-25	버크 인스티튜트 포 리서치 온 에이징	스트레스-유도성 p-tau 를 낮추는 트리아졸로피리딘 및 트리아졸로피리미딘
EP3341362B1 (en)	2015-08-27	2023-07-05	Nantneuro, LLC	Compositions for app-selective bace inhibition and uses therfor
US10702571B2 (en)	2015-12-03	2020-07-07	The University Of North Carolina At Pembroke	Materials for cathepsin B enhancement and methods of use
US10532102B2 (en)	2016-08-19	2020-01-14	Foresee Pharmaceuticals Co., Ltd.	Pharmaceutical composition and methods of uses
MX387820B (es) *	2016-08-19	2025-03-18	Foresee Pharmaceuticals Co Ltd	Composición farmacéutica y métodos de usos.
CN107468690B (zh)	2017-08-11	2020-01-31	北京卓凯生物技术有限公司	4-氧-烷基化特特拉姆酸类化合物及其制备方法与应用
CN107353239B (zh)	2017-08-11	2019-06-18	北京卓凯生物技术有限公司	4-氧-烷基化特特拉姆酸类化合物及其制备方法
US20210101879A1 (en) *	2018-03-01	2021-04-08	The Regents Of The University Of California	AMYLOID PROTEIN-SELECTIVE BACE INHIBITORS (ASBIs) FOR ALZHEIMER?S DISEASE
CN110652516A (zh) *	2018-06-29	2020-01-07	上海绿谷制药有限公司	甘露糖醛二酸的组合物在治疗帕金森氏症中的应用
WO2020117560A1 (en) *	2018-12-04	2020-06-11	The Brain Protection Company PTY LTD	Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use
US12208027B2 (en)	2018-12-04	2025-01-28	The Brain Protection Company PTY LTD	Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use
US11926599B1 (en)	2023-10-23	2024-03-12	King Faisal University	1-(2-chlorobenzylideneamino)-5,5-diphenylimidazolidine-2,4-dione as an antimicrobial compound

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS4995971A (2) *	1973-01-27	1974-09-11
DE2448869A1 (de)	1973-10-19	1975-09-04	Mcneilab Inc	4-oxo-2-imidazolidinylidenharnstoffe, verfahren zu ihrer herstellung und arzneimittel
US4025517A (en) *	1975-06-23	1977-05-24	Mcneil Laboratories, Incorporated	4-Oxo-2-hexahydropyrimidinylidene ureas
JPS554305A (en) *	1978-06-13	1980-01-12	Nippon Zoki Pharmaceut Co Ltd	Remedy for disease caused by stress and its preparation
US4864028A (en) *	1983-09-14	1989-09-05	Alcon Laboratories, Inc.	Spiro-tricyclicaromatic succinimide derivatives
US5070100A (en) *	1983-09-14	1991-12-03	Alcon Laboratories, Inc.	Spiro-tricyclicaromatic succinimide derivatives
GB2189699A (en)	1986-04-30	1987-11-04	Haessle Ab	Coated acid-labile medicaments
GB2189698A (en)	1986-04-30	1987-11-04	Haessle Ab	Coated omeprazole tablets
CH677886A5 (2)	1989-06-26	1991-07-15	Hans Georg Prof Dr Weder
US5387742A (en)	1990-06-15	1995-02-07	Scios Nova Inc.	Transgenic mice displaying the amyloid-forming pathology of alzheimer's disease
WO1992013069A1 (en)	1991-01-21	1992-08-06	Imperial College Of Science, Technology & Medicine	Test and model for alzheimer's disease
EP0620849B1 (en)	1992-01-07	2003-06-25	Elan Pharmaceuticals, Inc.	Transgenic animal models for alzheimer's disease
US5604102A (en)	1992-04-15	1997-02-18	Athena Neurosciences, Inc.	Methods of screening for β-amyloid peptide production inhibitors
AU702293B2 (en)	1993-10-27	1999-02-18	Athena Neurosciences, Inc.	Transgenic animals harboring APP allele having Swedish mutation
US5877399A (en)	1994-01-27	1999-03-02	Johns Hopkins University	Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
ES2094688B1 (es)	1994-08-08	1997-08-01	Cusi Lab	Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
FR2730932B1 (fr)	1995-02-27	1997-04-04	Oreal	Nanoemulsion transparente a base de lipides amphiphiles non-ioniques fluides et utilisation en cosmetique ou en dermopharmacie
US5942400A (en)	1995-06-07	1999-08-24	Elan Pharmaceuticals, Inc.	Assays for detecting β-secretase
US5744346A (en)	1995-06-07	1998-04-28	Athena Neurosciences, Inc.	β-secretase
FR2742676B1 (fr)	1995-12-21	1998-02-06	Oreal	Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie
FR2755854B1 (fr)	1996-11-15	1998-12-24	Oreal	Nanoemulsion a base de lipides amphiphiles non-ioniques et cationiques et utilisations
FR2760970B1 (fr)	1997-03-18	2000-03-10	Oreal	Nanoemulsions a base de lipides amphiphiles non-ioniques et de silicones aminees et utilisations
AU5002399A (en)	1998-07-17	2000-02-07	National Broach And Machine Company	Full form roll finishing technique
CN1300320C (zh)	1998-09-24	2007-02-14	法玛西雅厄普约翰美国公司	阿尔茨海默氏疾病分泌酶
FR2787026B1 (fr)	1998-12-14	2001-01-12	Oreal	Nanoemulsion a base d'esters mixtes d'acide gras ou d'alcool gras, d'acide carboxylique et de glyceryle, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787027B1 (fr)	1998-12-14	2001-01-12	Oreal	Nanoemulsion a base d'esters gras de sucre ou d'ethers gras de sucre et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787326B1 (fr)	1998-12-17	2001-01-26	Oreal	Nanoemulsion a base d'esters gras de glycerol, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787325B1 (fr)	1998-12-17	2001-01-26	Oreal	Nanoemulsion a base d'esters gras de sorbitan oxyethylenes ou non oxyethylenes, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2787728B1 (fr)	1998-12-23	2001-01-26	Oreal	Nanoemulsion a base d'esters gras d'acide phosphorique, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2787703B1 (fr)	1998-12-29	2001-01-26	Oreal	Nanoemulsion a base d'ethers gras ethoxyles ou d'esters gras ethoxyles, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788007B1 (fr)	1999-01-05	2001-02-09	Oreal	Nanoemulsion a base de copolymeres blocs d'oxyde d'ethylene et d'oxyde de propylene, et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
FR2788449B1 (fr)	1999-01-14	2001-02-16	Oreal	Nanoemulsion a base de citrates d'alkylether, et ses utilisations dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
FR2789076B1 (fr)	1999-02-02	2001-03-02	Synthelabo	Derives de alpha-azacyclomethyl quinoleine, leur preparation et leur application en therapeutique
US7161962B1 (en)	1999-05-27	2007-01-09	Nuera Communications, Inc.	Method and apparatus for coding modem signals for transmission over voice networks
FR2811564B1 (fr)	2000-07-13	2002-12-27	Oreal	Nanoemulsion contenant des polymeres non ioniques, et ses utilisations notamment dans les domaines cosmetique, dermatologique, pharmaceutique et/ou ophtalmologique
AU2002241823A1 (en)	2001-01-11	2002-07-24	Eastman Chemical Company	Cyclodextrin sulfonates, guest inclusion complexes, methods of making the same and related materials
FR2819427B1 (fr)	2001-01-18	2003-04-11	Oreal	Nanoemulsion translucide, son procede de fabrication et ses utilisations dans les domaines cosmetique, dermatologique et/ou ophtalmologique
WO2004030608A2 (en)	2001-06-05	2004-04-15	The Regents Of The University Of Michigan	Nanoemulsion vaccines
US7476393B2 (en)	2002-11-29	2009-01-13	L'oreal	Process for the preparation of a cationic nanoemulsion, and cosmetic composition
ES2323068T3 (es)	2003-08-08	2009-07-06	Schering Corporation	Inhibidores de bace-1 de aminas ciclicas con un sustituyente de benzamida.
MXPA06001558A (es)	2003-08-08	2006-05-15	Schering Corp	Inhibidores de amina ciclica bace-1 que poseen un sustituyente heterociclico.
PT1699455E (pt)	2003-12-15	2013-08-27	Merck Sharp & Dohme	Inibidores de protease de aspartilo heterocíclicos
US7592348B2 (en)	2003-12-15	2009-09-22	Schering Corporation	Heterocyclic aspartyl protease inhibitors
US7763609B2 (en)	2003-12-15	2010-07-27	Schering Corporation	Heterocyclic aspartyl protease inhibitors
US7468402B2 (en)	2004-03-17	2008-12-23	Baker Hughes Incorporated	Polymeric nanoemulsion as drag reducer for multiphase flow
CA2561532A1 (en)	2004-04-02	2005-10-20	Merck & Co., Inc.	Methods for detecting substances which bind to the amyloid precursor protein or beta amyloid fragments, and binding compounds
WO2005108358A2 (en)	2004-04-22	2005-11-17	Eli Lilly And Company	Pyrrolidine derivatives useful as bace inhibitors
IL162288A0 (en)	2004-06-01	2005-11-20	Future Products Man S A	Compositions and methods for treating neurodegenerative disorders
CA2578600A1 (en)	2004-06-16	2006-01-26	Wyeth	Diphenylimidazopyrimidine and -imidazole amines as inhibitors of b-secretase
BRPI0512213A (pt)	2004-06-16	2008-02-19	Wyeth Corp	método para tratamento, prevenção ou melhora de uma doença ou distúrbio; composição farmacêutica; processo para a preparação de um composto; e uso de um composto
EP1781625B1 (en)	2004-07-22	2010-12-15	Schering Corporation	Substituted amide beta secretase inhibitors
DE602005007245D1 (2)	2004-07-28	2008-07-10	Schering Corp
TW200624426A (en)	2004-09-21	2006-07-16	Lilly Co Eli	BACE inhibitors
US20080132477A1 (en)	2005-01-13	2008-06-05	Claudia Betschart	Macrocyclic Compounds Useful as Bace Inhibitors
GB0500683D0 (en)	2005-01-13	2005-02-23	Novartis Ag	Organic compounds
AU2006259609A1 (en)	2005-06-14	2006-12-28	Pharmacopeia, Inc.	Aspartyl protease inhibitors
CN101198597B (zh)	2005-06-14	2011-11-16	先灵公司	作为天冬氨酰基蛋白酶抑制剂的化合物的制备和用途
MX2007016180A (es)	2005-06-14	2008-03-07	Schering Corp	Inhibidores de aspartil proteasas.
JP2008543840A (ja)	2005-06-14	2008-12-04	シェーリングコーポレイション	アスパルチルプロテアーゼインヒビター
MX2007016186A (es)	2005-06-14	2008-03-07	Schering Corp	Preparacion y uso de inhibidores de proteasas.
RU2008100164A (ru)	2005-06-14	2009-07-20	Шеринг Корпорейшн (US)	Получение и применение соединений в качестве ингибиторов протеаз
CA2609562A1 (en)	2005-06-14	2006-12-28	Schering Corporation	Macrocyclic heterocyclic aspartyl protease inhibitors
TW200738683A (en)	2005-06-30	2007-10-16	Wyeth Corp	Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
WO2007005404A1 (en) *	2005-06-30	2007-01-11	Wyeth	AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION
TW200730523A (en) *	2005-07-29	2007-08-16	Wyeth Corp	Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
EP1928841A1 (en) *	2005-09-26	2008-06-11	Wyeth a Corporation of the State of Delaware	Amino-5- ý4- (difluoromethoxy) phenyl¨-5-phenylimidazolone compounds as inhibitors of the beta-secretase (bace)
WO2007050721A2 (en)	2005-10-27	2007-05-03	Schering Corporation	Heterocyclic aspartyl protease inhibitors
PE20070798A1 (es)	2005-10-31	2007-08-24	Schering Corp	Compuestos heterociclicos como inhibidores de aspartil proteasas
JP2009520686A (ja) *	2005-11-21	2009-05-28	アストラゼネカ・アクチエボラーグ	新規な２−アミノ−イミダゾール−４−オン化合物並びに認知障害、アルツハイマー病、神経変性及び認知症の治療に使用する医薬の製造におけるその使用
GB0602951D0 (en)	2006-02-14	2006-03-29	Novartis Ag	Organic Compounds
US20090099217A1 (en)	2006-04-05	2009-04-16	Astex Therapeutics Ltd.	2-Aminopyrimidin-4-Ones And Their Use For Treating Or Preventing Alpha Beta-Related Pathologies
GB0611064D0 (en)	2006-06-05	2006-07-12	Novartis Ag	Organic compounds
KR20090015967A (ko)	2006-06-12	2009-02-12	쉐링 코포레이션	헤테로사이클릭 아스파르틸 프로테아제 억제제
TW200815443A (en)	2006-06-14	2008-04-01	Astrazeneca Ab	Novel compounds I
TW200815449A (en)	2006-06-14	2008-04-01	Astrazeneca Ab	Novel compounds II
TW200815447A (en)	2006-06-14	2008-04-01	Astrazeneca Ab	Novel compounds IV
TW200808796A (en)	2006-06-14	2008-02-16	Astrazeneca Ab	New compounds III
TW200815349A (en)	2006-06-22	2008-04-01	Astrazeneca Ab	New compounds
CA2656869A1 (en)	2006-07-20	2008-01-24	Novartis Ag	Macrocyclic lactams
JP2009544599A (ja)	2006-07-20	2009-12-17	ノバルティスアクチエンゲゼルシャフト	Ｂａｃｅ阻害剤として有用な大環状化合物
AU2007324490A1 (en)	2006-11-23	2008-05-29	Novartis Ag	2-hydroxy-1,3-diaminopropane derivatives
AU2007332754A1 (en)	2006-12-12	2008-06-19	Schering Corporation	Aspartyl protease inhibitors
CN101631779A (zh)	2006-12-12	2010-01-20	先灵公司	含有三环系统的天冬氨酰蛋白酶抑制剂
TW200831091A (en) *	2006-12-20	2008-08-01	Astrazeneca Ab	New compounds
JP2010521457A (ja)	2007-03-12	2010-06-24	メルク・シャープ・エンド・ドーム・コーポレイション	単環式アニリドスピロラクタムｃｇｒｐ受容体アンタゴニスト
PE20090160A1 (es) *	2007-03-20	2009-02-11	Wyeth Corp	COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
TW200902499A (en)	2007-05-15	2009-01-16	Astrazeneca Ab	New compounds
US20090041201A1 (en)	2007-08-06	2009-02-12	Carestream Health, Inc.	Alignment apparatus for imaging system
WO2009024615A1 (en)	2007-08-23	2009-02-26	Novartis Ag	Aminobenzyl-substituted cyclic sulfones useful as bace inhibitors
US20090062361A1 (en)	2007-08-30	2009-03-05	Allergan, Inc.	Therapeutic hydantoins
TWI431004B (zh)	2008-05-02	2014-03-21	Lilly Co Eli	Ｂａｃｅ抑制劑
EP2303857A1 (en)	2008-07-10	2011-04-06	Novartis AG	Cyclic sulfones with aminobenzyl substitution useful as bace inhibitors
CN102186841A (zh)	2008-10-22	2011-09-14	盐野义制药株式会社	具有bace1抑制活性的2-氨基嘧啶-4-酮及2-氨基吡啶衍生物
ES2438294T3 (es)	2008-11-11	2014-01-16	Cspc Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd.	Complejos de inclusión de pinocembrina con ciclodextrina o sus derivados
AR077277A1 (es)	2009-07-09	2011-08-17	Lilly Co Eli	Compuestos de biciclo (1,3)tiazin-2-amina formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento util para el tratamiento de la enfermedad de alzheimer
UA108363C2 (uk)	2009-10-08	2015-04-27		Похідні імінотіадіазиндіоксиду як інгібітори bace, композиція на їх основі і їх застосування
US8563543B2 (en)	2009-10-08	2013-10-22	Merck Sharp & Dohme Corp.	Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
JP6250394B2 (ja)	2010-08-19	2017-12-20	バック・インスティテュート・フォー・リサーチ・オン・エイジング	軽度の認知障害（ｍｃｉ）および関連障害の処置方法
US8415483B2 (en)	2010-12-22	2013-04-09	Astrazeneca Ab	Compounds and their use as BACE inhibitors
US20120165346A1 (en)	2010-12-22	2012-06-28	Astrazeneca Ab	Compounds and their use as BACE inhibitors
US8877744B2 (en)	2011-04-04	2014-11-04	Hoffmann-La Roche Inc.	1,4-Oxazepines as BACE1 and/or BACE2 inhibitors
US20140371283A1 (en)	2013-02-12	2014-12-18	Buck Institute For Research On Aging	Hydantoins that modulate bace-mediated app processing
EP3341362B1 (en) *	2015-08-27	2023-07-05	Nantneuro, LLC	Compositions for app-selective bace inhibition and uses therfor

2014
- 2014-02-12 US US14/179,310 patent/US20140371283A1/en not_active Abandoned
- 2014-02-12 JP JP2015557226A patent/JP6471100B2/ja active Active
- 2014-02-12 DK DK14751458.2T patent/DK2956443T3/da active
- 2014-02-12 ES ES19199279T patent/ES2975235T3/es active Active
- 2014-02-12 CA CA2899938A patent/CA2899938C/en active Active
- 2014-02-12 CN CN201480007825.4A patent/CN104995176B/zh active Active
- 2014-02-12 ES ES14751458T patent/ES2769578T3/es active Active
- 2014-02-12 KR KR1020157021979A patent/KR102051485B1/ko active Active
- 2014-02-12 AU AU2014216390A patent/AU2014216390B2/en active Active
- 2014-02-12 EP EP19199279.1A patent/EP3653609B1/en active Active
- 2014-02-12 KR KR1020197035067A patent/KR102220259B1/ko active Active
- 2014-02-12 EP EP14751458.2A patent/EP2956443B1/en active Active
- 2014-02-12 WO PCT/US2014/016100 patent/WO2014127042A1/en not_active Ceased
- 2014-02-12 US US14/764,107 patent/US10202355B2/en active Active
2015
- 2015-08-12 IL IL240555A patent/IL240555B/en active IP Right Grant
- 2015-10-30 US US14/928,775 patent/US9926280B2/en active Active
2017
- 2017-12-06 US US15/833,862 patent/US10766867B2/en active Active
2019
- 2019-01-17 JP JP2019005905A patent/JP6773820B2/ja active Active
- 2019-02-08 US US16/271,681 patent/US20200017449A1/en not_active Abandoned
2020
- 2020-01-10 US US16/740,110 patent/US11091444B2/en active Active

Publication	Publication Date	Title
JP2016507575A5 (2)	2017-02-23
JP2016505637A5 (2)	2017-02-23
JP2013537203A5 (2)	2014-05-22
JP2016505614A5 (2)	2017-02-16
JP2016506962A5 (2)	2017-03-02
JP2016515561A5 (2)	2017-05-18
JP2010511721A5 (2)	2011-01-27
JP2017509586A5 (2)	2018-01-11
JP2016040288A5 (2)	2016-05-12
JP2015512931A5 (2)	2016-05-26
JP2019517487A5 (2)	2020-07-02
JP2017504611A5 (2)	2018-02-01
JP2016506960A5 (2)	2017-03-02
JP2015508749A5 (2)	2015-06-18
JP2012508252A5 (2)	2014-09-04
JP2013533879A5 (2)	2014-07-03
JP2011519956A5 (ja)	2012-04-12	キナゾリン誘導体及び同キナゾリン誘導体を含む治療薬
JP2014525420A5 (2)	2015-10-15
JP2020097577A5 (2)	2020-10-08
JP2016503797A5 (2)	2016-12-28
JP2016516043A5 (2)	2017-04-13
JP2016506961A5 (2)	2017-03-02
JP2011513410A5 (2)	2012-04-12
JP2016531126A5 (2)	2017-09-28
JP2016130266A5 (2)	2016-12-01